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Abstract Small GTPases of the Rab family regulate membrane
transport pathways. More than 50 mammalian Rab proteins are
known, many with transport step-specific localisation. Rabs must
associate with cellular membranes for activity and membrane
attachment is mediated by prenyl (geranylgeranyl) post-transla-
tional modification. Mutations in genes encoding proteins
essential for the geranylgeranylation reaction, Rab escort protein
and Rab geranylgeranyl transferase, underlie genetic diseases.
Choroideremia patients have loss of function mutations in REP1
and the murine Hermansky^Pudlak syndrome model gunmetal
possesses a splice-site mutation in the K-subunit of RGGT. Here
we discuss recent insights into Rab prenylation and advances
towards our understanding of both diseases. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Rab proteins are small GTP-binding proteins which form
the largest family within the Ras-like GTPase superfamily.
Rabs are believed to regulate membrane transport pathways
by acting as molecular switches that alternate between active
(GTP-bound) and inactive (GDP-bound) conformations. In
their active GTP-bound conformation, Rabs ful¢l their role
in vesicle formation, organelle movement and membrane teth-
ering/fusion by recruiting a diverse group of e¡ector proteins
[1^4]. More than 50 Rab proteins have been identi¢ed in
mammalian cells [5]. Each Rab is believed to be localised to
a speci¢c subcellular compartment and some show tissue-spe-
ci¢c variation in expression level, re£ecting the complexity
and variety of tra⁄cking events found in mammalian cells
[1^4].
2. Prenylation of Rab proteins
Rab proteins are intrinsically soluble proteins, whose activ-
ity is dependent upon association with the cytoplasmic lea£et
of cellular membranes. This association is mediated by a lipid
modi¢cation of the C-terminus termed prenylation. Prenyla-
tion is a common mechanism for membrane association of
cytoplasmic proteins, estimated to a¡ect approximately 0.5%
of all intracellular proteins [6]. Prenylation consists of the
covalent attachment, via thioether linkage, of a C15 (farnesyl)
or C20 (geranylgeranyl) isoprenoid group to a C-terminal cys-
teine residue in the context of a ‘prenylation motif’.
Protein prenylation is catalysed by protein prenyl transfer-
ases of which three enzymes are known: protein farnesyl
transferase (PFT), protein geranylgeranyl transferase-type I
(PGGTI, also known as CAAX-GGT), and Rab geranylger-
anyl transferase (RGGT, also known as PGGTII). All three
enzymes are heterodimers consisting of an K- and L-subunit
[7].
PFT and PGGTI, which share a common K-subunit, de¢ne
the functional class of CAAX prenyl transferases. They recog-
nise a CAAX tetrapeptide prenylation motif at the C-terminus
of their substrates, where C represents a cysteine residue, A an
aliphatic residue and X any amino acid. The identity of the
residue at position X is su⁄cient to determine which enzyme
will modify which protein. When X is a methionine or serine,
as in Ras proteins, then the protein is farnesylated by PFT.
However, when X is a leucine residue, as in Rho proteins,
then the protein is geranylgeranylated by PGGTI [8,9].
CAAX prenylation motifs are also found in a variety of other
proteins such as Q-subunits of heterotrimeric G-proteins, nu-
clear lamins, G-protein-coupled receptor kinases, fungal mat-
ing pheromones and retinal cyclic GMP phosphodiesterase
[8,9].
RGGT de¢nes a second class of prenyl transferases which
di¡ers in many ways from the CAAX prenyl transferases.
RGGT was originally identi¢ed as the enzyme that modi¢ed
Rab proteins, and so far no other substrates are known
[10,11]. The structure of RGGT has been solved recently
[12]. The L-subunit consists of an K^K barrel and forms the
lipid-binding site as shown for PFT [11^13]. The K-subunit is
larger than that found in the CAAX prenyl transferases, con-
sisting of a helical domain similar to PFT plus two other
domains of unknown function: a leucine-rich repeat and an
immunoglobulin-like domain [12].
Rab proteins, unlike other small GTPases, exhibit a variety
of prenylation motifs at their C-termini, containing either one
or, more frequently, two cysteine residues, both of which are
modi¢ed by geranylgeranyl groups [14]. Also, the prenylation
motif in Rab proteins is insu⁄cient by itself for substrate
recognition by RGGT. Biochemical evidence indicates that
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 4 8 3 - 8
*Corresponding author. Fax: (44)-20-7594 3015.
E-mail: m.seabra@ic.ac.uk
FEBS 24908 5-6-01 Cyaan Magenta Geel Zwart
FEBS 24908 FEBS Letters 498 (2001) 197^200
unprenylated Rab must ¢rst bind to a 95 kDa protein termed
Rab escort protein (REP, originally termed component A of
RGGT) in order to be recognised as a substrate for RGGT
[11,15]. The role of REP in prenylation is supported by the
¢nding that de¢ciency of REP results in hypoprenylation of
Rab proteins in vivo [16,17]. Together these observations sug-
gest that the REP:Rab complex is the true substrate of
RGGT [11,14].
Two REP proteins are found in mammals [18]. Both REP1
and REP2 are ubiquitously expressed and are structurally
related to another Rab-binding protein, Rab GDP dissocia-
tion inhibitor (RabGDI), which is thought to catalyse the
insertion and retrieval of prenylated Rab proteins into and
out of cellular membranes [11,19]. Recent results suggest
that REPs and GDIs interact with Rab proteins in a con-
served way, using amino acid residues in the conserved
‘Rab-binding platform’ [20]. Conserved positions that distin-
guish Rab proteins from other small GTPases, RabF motifs,
are likely involved in the binding of Rab to REPs and GDIs
[5,21,22].
Rab prenylation occurs in several steps (Fig. 1). Newly syn-
thesised Rabs bind to one of the two REP proteins and this
complex then associates with RGGT. This enzyme contains
one GGPP-binding site and recent studies indicate that
GGPP-binding increases the a⁄nity of RGGT for the RE-
P:Rab complex suggesting that the enzyme may already be
bound to a single GGPP group at this stage [23,24]. Geranyl-
geranylation of the most N-terminal cysteine follows [25]. In
the case of some Rabs, e.g. Rab8 or Rab13, which contain a
lone cysteine residue available for prenylation, dissociation of
the enzyme occurs at this point. However, a second cysteine
residue is available in most cases and RGGT catalyses anoth-
er round of lipid-binding and transfer. In this case, it is un-
clear whether RGGT dissociates from the mono-prenylated
REP:Rab-GG complex, due to the reduction in the a⁄nity
of RGGT for the mono-prenylated complex in the absence of
GGPP, or whether it can recruit a second geranylgeranyl
group while bound to the REP:Rab-GG complex. Finally,
after the second GG group is transferred, binding of an addi-
tional lipid group to the L-subunit destabilises the complex
and the enzyme dissociates from the di-prenylated REP:Rab
complex. [24]. REP may then deliver the geranylgeranylated
Rab to cellular membranes [26,27] where it can interact with
speci¢c e¡ectors and perform its biological role.
Fig. 1. Rab prenylation and disease of mice and man. Newly synthesised Rabs bind to one of two REP proteins. Mutations in REP1 cause
CHM, an X-linked retinal degeneration. Histologic sections of retina reveal early pathological changes in a female carrier of the CHM muta-
tion (A), and the fundus of the eye of an a¡ected male shows marked peripheral retinal degeneration (B). The REP:Rab complex is the sub-
strate for the enzyme RGGT which catalyses geranylgeranylation of the Rab protein. Mutations in the K-subunit of RGGT result in hypopig-
mentation as observed in the gm mouse model of HPS (C) and platelet dysfunction characterised by macrothrombocytopenia and reduced
number of K- and dense granules (D). Mutations in one Rab protein, Rab27a, result in hypopigmentation as observed in the ash mouse model
of GS (E), due to clustering of melanosomes in the perinuclear region of melanocytes (F). Inset in F shows normal distribution of melanosomes
in wild-type melanocytes.
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3. REP and choroideremia (CHM)
CHM is an X-linked chorioretinal degeneration character-
ised by progressive night blindness and loss of peripheral vi-
sion starting in the second or third decade of life which in-
variably results in complete blindness within two or three
decades of the initial manifestation of symptoms [28,29].
The gene mutated in this disease was identi¢ed by Cremers
and co-workers [30] and named CHM. All known CHM mu-
tations are predicted to result in loss of CHM protein function
due to the production of truncated, non-functional or unsta-
ble polypeptides [29].
A function of CHM became apparent when REP1 was
puri¢ed and cloned, and observed to correspond to the
CHM gene product [28,31]. This suggested that CHM was
caused by improper Rab prenylation, but it remained unclear
how loss of a function essential for every cell type resulted in
an eye-speci¢c phenotype. The observation that lymphoblasts
from CHM patients still contained RGGT activity led to the
identi¢cation of a second REP protein, REP2, and to the
hypothesis that REP2 incompletely compensates the loss of
REP1 in CHM patients thus leaving a subset of Rab proteins
unprenylated [32]. Consistent with this hypothesis, one Rab
protein was observed to be selectively unprenylated in CHM
lymphoblasts [33]. This Rab was subsequently identi¢ed as
Rab27a and shown to be highly expressed in the same layers
of the rat eye that are observed to degenerate in CHM pa-
tients, the retinal pigment epithelium (RPE) and the choroid
[33].
Rab27a, one of two isoforms of the Rab27 subfamily, was
recently shown to localise to melanosomes, melanin contain-
ing granules present in melanocytes, and to be involved in the
transport of these organelles to the periphery of melanocytes
[34^36]. Therefore, one possibility is that retinal degeneration
in CHM patients might be triggered by defects in transport of
melanosomes in RPE and choroidal melanocytes. However,
recent data call into question the relationship between
Rab27a hypoprenylation and chorioretinal cell death. Firstly,
Rab27a is highly expressed in a number of other tissues which
are apparently una¡ected in CHM patients [33,37,38]. Sec-
ondly, loss of function mutations in the human and murine
RAB27A genes result in Griscelli syndrome (GS) and the
ashen (ash) mutant mouse, respectively. GS is characterised
by partial cutaneous albinism and immunode¢ciency, neither
of which is reported as a¡ecting CHM patients [36,39]. In
both GS patients and the ash mouse, the absence of Rab27a
protein results in immunode¢ciency due to failure of cytotoxic
T lymphocytes to secrete the contents of their lytic granules
[39^41], and albinism due to defects in melanosome transport
[34^36].
In spite of these observations, the involvement of Rab27a in
the pathogenesis of CHM cannot be discounted at present as
the ash mutant examined in the above studies is maintained in
the inbred laboratory mouse strain (C3H) which is homozy-
gous for the rd mutation [42]. This mutation of the L-subunit
of cyclic GMP phosphodiesterase causes complete degenera-
tion of photoreceptors shortly after birth. The absence of
observed retinal degeneration in GS is understandable as their
mean life expectancy is 5 years in the absence of early bone
marrow transplantation [43] and to our knowledge no reports
of long term health of transplanted patients are published. In
our view, it is still likely that dysfunction of Rab27a contrib-
utes to CHM pathogenesis perhaps in combination with other
retinal Rabs similarly hypoprenylated and partially dysfunc-
tional. Another possibility is that REP1 may have other func-
tions yet undiscovered required for survival of retinal cells.
4. RGGT and Hermansky^Pudlak syndrome (HPS)
HPS is a group of recessively inherited disorders caused by
mutation in multiple genes whose products are involved in the
biogenesis and function of three related organelles: melano-
somes in melanocytes, platelet dense granules and lysosomes.
The disease manifests as hypopigmentation (partial albinism),
prolonged bleeding and ceroid deposition in lysosomes
[44,45].
The gunmetal (gm) mutant is one of 14 murine models of
HPS. In addition to the above defects, the gm mutant exhibits
other abnormalities relative to wild-type animals; they have
fewer, larger platelets, reduced platelet K-granule content, and
reduction in killing capacity of cytotoxic T cells [40,46]. Re-
cently, the gm mutation was identi¢ed as a G to A substitu-
tion in a splice-acceptor site in the gene encoding the murine
RGGT K-subunit [47]. As a consequence, the major RGGT
transcript in the gm mutant lacks a start codon and is non-
functional. However, the gm mutant contains a reduced level
of RGGT activity due to the low frequency activation of a
cryptic splice-acceptor site within RGGT-K RNA, which re-
sults in the production of a transcript containing a start co-
don.
This observation suggested that de¢ciency of Rab(s) preny-
lation results in the HPS phenotype, a hypothesis remarkably
similar to the one proposed for CHM. Consistent with this
possibility, a subset of Rabs accumulate unprenylated in gm
cytosol, including Rab27a [40,46,47]. Interestingly, Rab27 iso-
forms are highly expressed in the tissues a¡ected in the gm
mouse suggesting that the gm phenotype is at least in part a
result of reduced Rab27 function. However, a number of ob-
servations indicate that hypoprenylation-induced defects in
the function of other unknown Rabs contribute signi¢cantly
towards more general disruption of membrane transport
which triggers the pathological changes observed in this mu-
tant. The most obvious of these is that although both the gm
and ash mutants exhibit hypopigmentation and immunode¢-
ciency, the fundamental cell biological defects underlying
these phenotypes di¡er. In gm, immunode¢ciency appears to
result from defects in T cell cytotoxic granule polarisation
rather than in secretion of granule contents as observed in
ash [40]. Our preliminary observations of melanosome distri-
bution in melanocytes derived from gm neonates indicate that
hypopigmentation in this mutant does not result from failure
to transport melanosomes to the peripheral cytoplasm (E.
Sviderskaya, A.N. Hume, D.C. Bennet and M.C. Seabra, un-
published observations) as is observed in ash [36]. Identi¢ca-
tion and characterisation of the other Rabs which accumulate
unprenylated in the cytosol of gm mutant should provide
further insight into Rab prenylation and function, the patho-
genesis of HPS and other human lysosomal storage disorders.
5. Conclusions
In conclusion, de¢ciencies in the Rab prenylation machi-
nery can lead to di¡erent diseases (Fig. 1). Hypoprenylation
of one or more Rab proteins seems to be the cause of the
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di¡erent diseases, although it is impossible to rule out at this
point other molecular mechanisms. It is intriguing that while
prenylation is required for the function of most Rab proteins,
de¢ciencies in the prenylation machinery only a¡ect certain
tissues. A possible explanation is that these restricted pathol-
ogies result from members of the Rab family having a range
of a⁄nities for REP1, REP2 and/or RGGT, together with a
di¡erential tissue requirement.
Rab27 appears to be a common denominator in CHM and
gm, suggesting that it is not a good substrate for prenylation.
As we cannot detect signi¢cant di¡erences in binding of REP1
and REP2 to Rab27 in vitro (B. Larijani and M.C. Seabra,
unpublished observations), other yet undescribed factors may
regulate Rab prenylation in vivo. If this is the case, elucidat-
ing the nature of these factors will bring further insight to the
understanding of Rab prenylation and these pathologies.
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